JPRN-jRCTs071190001暂停4 期
Continuation of certolizumab pegol with Or Without MTX in RA patients achieving sustained remissioN and low disease activity - CROWN study
Miyazaki Yusuke0 个研究点目标入组 150 人开始时间: 2019年4月2日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 暂停
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients aged over 16 years (at the time of informed consent)
- •2) Patients diagnosed with rheumatoid arthritis (RA) under the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) criteria
- •3) Patients who have been receiving combination therapy with MTX ( over 6 mg/week) and CZP for 24 weeks before enrollment of the study
- •4) Patients who showed SDAI less than 11 at any visit for over 3 months before enrollment without taking any steroids
- •5) Patients who provided written informed consent
排除标准
- •Patients judged by the investigator to be unsuitable for participants in the study
研究者
相似试验
招募中
不适用
Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-stateRheumatoid arthritisJPRN-jRCTs041200048Asai Shuji88
已完成
不适用
Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritisrheumatoid arthritisJPRN-UMIN000014486Saitama East Study Group100
已完成
不适用
Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitorRheumatoid arthritisJPRN-UMIN000020154Saitama Medical University, Department of Rheumatology and Applied Immunology150
已完成
3 期
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00753454UCB Pharma168
进行中（未招募）
1 期
Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled studyPrediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)EUCTR2013-000337-13-PTniversitätsklinikum Erlangen156